Clinicopathological Characteristics and the First Mutational Analysis of Gastrointestinal Stromal Tumors From Mexico: A Single Institution Experience

• Published in: Curēus (Palo Alto, CA) CA), 2024-06, Vol.16 (6), p.e62594
• Main Authors: Medrano Guzman, Rafael, Perez Ventura, Edgar F, Arias Rivera, Atl Simon, Piña-Sanchez, Patricia, Brener Chaoul, Moises
• Format: Article
• Language: English
• Subjects: Gastroenterology; Gastrointestinal cancer; Genetics; Kinases; Mutation; Oncology; Response rates; Small intestine; Survival analysis; Tumors
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.62594

Background Gastrointestinal stromal tumors (GISTs) arise from Cajal's interstitial cell precursors and display a variety of genetic mutations, primarily in the and genes. These mutations are linked to tumor location, prognosis, and response to treatment. This study delves into the mutational patterns of GISTs in a Mexican population and their impact on overall survival (OS) and disease-free survival (DFS). Methodology This retrospective study examined 42 GIST cases diagnosed at the Oncology Hospital of the National Medical Center XXI Century between January 2018 and December 2020. Clinical, histological, and immunohistochemical data were gathered, and mutational analysis of and genes was conducted using second-generation sequencing. Results The study group consisted of 52.4% females and 47.6% males, with an average age of 62.6 years. The most common tumor site was the stomach (59.5%), followed by the small intestine (26.2%). mutations were detected in 71.4% of cases, predominantly involving exon 11. mutations were observed in 7.1% of cases. Recurrence was noted in 9.5% of patients, all with high-risk tumors. No significant link was identified between specific mutations and OS or DFS. Conclusions This investigation sheds light on the genetic landscape of GISTs in the Mexican population. While no significant association was established between particular mutations and survival outcomes, the study emphasizes the importance of molecular profiling in treatment decision-making. Further studies with larger sample sizes and longer follow-up periods are necessary to validate these results and explore their clinical relevance.